63 results about "Human platelet" patented technology

The invention provides an anti-human thrombopoietin antibody AF687, a kit and application thereof. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can accurately detect the content of human thrombopoietin in serum, is not influenced by heterogeneity of natural protein glycosylation sites, can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia, and has the advantages that compared with an existing detection reagent, the anti-human thrombopoietin antibody is high in sensitivity and high in sensitivity. The false positive rate can be reduced from 13.9% to 2.7%, and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

A method for preparing exosomes is provided. The method includes preparing a human platelet, treating the human platelet with a buffer to obtain a platelet solution, centrifuging the platelet solution, and collecting supernatant of the centrifuged platelet solution to obtain an exosome solution. The buffer is calcium ion buffer, phosphate buffered saline (PBS), tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) buffer, or 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) buffer.

The present invention addresses the problem of providing a new method for efficiently isolating a mesenchymal stem cell as a single cell and efficiently proliferating the single cell.　Provided is a method for isolating a single mesenchymal stem cell from a cell population including mesenchymal stem cells, the method comprising: a first culture step for culturing the cell population in a first culture medium containing a human platelet lysate; a recovery step for recovering the cell population after the first culture step; and an isolation step for isolating a single mesenchymal stem cell from the cell population after the recovery step.

The present disclosure relates to a stable human platelet lysate composition; preferably a stable heparin-free human platelet lysate composition; methods for obtaining said composition and uses thereof.

The invention provides an anti-human thrombopoietin antibody AF692, a kit and application of the anti-human thrombopoietin antibody AF692. The anti-human thrombopoietin antibody disclosed by the invention can specifically recognize epitopes without glycosylation modification of natural TPO protein, and has relatively high affinity for recombinant TPO protein and specific epitopes of the recombinant TPO protein. Meanwhile, the anti-human thrombopoietin antibody disclosed by the invention can be used for accurately detecting the content of human thrombopoietin in serum, is not influenced by natural protein glycosylation site heterogeneity, and can be used for accurately identifying and diagnosing early aplastic anemia and primary immune thrombocytopenia; and a more accurate detection method is provided for differential diagnosis of the primary immune thrombocytopenia.

The invention belongs to the technical field of cell culture, and particularly relates to a serum-free mesenchymal stem cell culture medium and a preparation method thereof. The serum-free mesenchymal stem cell culture medium provided by the invention is prepared by taking a DMEM (Dulbecco Modified Eagle Medium) / F12 basal culture medium as a basis and adding supplementary factors, namely yeast hydrolysate, insulin, albumin, dexamethasone, taurine, salidroside, soy isoflavone, baicalein, human platelet lysate, momordica saponin and hyperoside. According to the serum-free mesenchymal stem cell culture medium provided by the invention, the normal form of cells can be maintained without supplementing serum, rapid proliferation is realized, and the biological characteristics of the mesenchymal stem cells are maintained.

The invention discloses a culture medium for adipose-derived stem cells, and particularly relates to the technical field of stem cell culture. The culture medium comprises a basic culture medium and nerve-vascular niche components, wherein the basic culture medium comprises DMEM / F12, 10% of human-derived platelet lysate and 1% of antibiotic solution; the nerve-vascular niche comprises the following components: a Slit3 recombinant protein, a nerve growth factor-beta, a glial cell-derived neurotrophic factor, a lysyl oxidase inhibitor, dexamethasone, 3-isobutyl-1-methylxanthine and insulin. The traditional fetal calf serum is replaced by the human-derived platelet lysate, so that the risks of immunological rejection and pathogen pollution are avoided; through the synergistic effect of nerve-vessel niche factors, blood vessel maturation and innervation are promoted, programmed mechanical stretching culture is combined, the adipogenic differentiation efficiency of adipose-derived stem cells is remarkably improved, and engineered adipose tissue which is huge in lipid droplet, compact in structure and provided with a nerve-vessel network is formed.

The invention relates to the technical field of cell biology, in particular to an iNKT cell cryopreservation solution and a method for cryopreserving iNKT cells by using the cryopreservation solution. The invention provides an immune cell cryopreservation solution. The immune cell cryopreservation solution comprises human serum albumin, a basic low-temperature protection solution and an optional human platelet lysate. The immune cell freezing medium does not contain animal-derived components except for human bodies, and has the advantages of simple components and good stability. According to the cryopreservation liquid disclosed by the invention, through the combined action of the basic low-temperature protection liquid (such as CryoStor10 (CS10)) and the human serum albumin, the motility rate after cell recovery is improved, and the damage to immune cells (such as iNKT) in the cryopreservation process is reduced. After a small amount of human platelet lysate is further added, the survival rate of cell resuscitation and the amplification capacity can be further improved.

The present application relates to a method for inducing pluripotent cells to proliferate and / or differentiate into megakaryocyte progenitor cells (MKPs), comprising adding a human platelet lysate (hPL) and an HDAC inhibitor to an MKP differentiation medium. The present application also provides a culture medium used in the method, and a composition comprising the culture medium.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

Disclosed are methods for selecting, expanding,and / or enriching cells that are resistant to an immunosuppressive agent (e.g., MTX), and the method comprising treating the cells with the immunosuppressive agent and human platelet lysate (HPL). In some embodiments, the cells (e.g., CAR-T cells) can be used for cell therapy.

The present application relates to a method for inducing proliferation and / or differentiation of pluripotent cells into megakaryocyte progenitor cells (MKP), comprising adding human platelet lysate (hPL) and an HDAC inhibitor to an MKP differentiation medium. The invention also provides a culture medium used by the method and a composition containing the culture medium.

The present invention discloses a cell cold storage protection solution and a preparation method and application thereof, and belongs to the field of cell preservation technology. The present invention provides a cell cold storage protection solution, the formula composition includes a compound electrolyte solution, red blood cell preservation solution, heparin sodium, human serum albumin, human platelet lysate and glucose. When preparing the cell cold storage protection solution, mix and prepare it under sterile conditions at room temperature. When the cell cold storage protection solution of the present invention is used to refrigerate a stem cell preparation, the activity of the stem cells is still above 85% after refrigeration for 96 hours, and the growth, proliferation and differentiation potential of the stem cells can be maintained.

The present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and / or treatment of inflammatory driven diseases, neurodegenerative diseases, immune / autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.

The present invention is in the field of in vitro assays, particularly in the field of pyrogen and endotoxin detection. The present invention provides improved compositions suitable for use in animal-free tests, for example, in monocyte activation tests. The improved compositions allow for increased sensitivity, improved dynamic range, and improved fidelity of test responses.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

Provided is a method for differentiating platelet cells, comprising adding a human platelet lysate (hPL) to a platelet differentiation culture medium. Further provided are a culture medium for differentiating platelets and use thereof.

The present invention provides a culture medium and a culture method for primary human acute lymphoblastic leukemia cells. The acute lymphoblastic leukemia cell culture medium of the present invention comprises a glutamine additive, non-essential amino acids, recombinant human FLT3 ligand, human interleukin-3, human interleukin-7, human interleukin-2, human stem cell factor, and human thrombopoietin. Using the culture medium and culture method of the present invention, acute lymphoblastic leukemia cells can be cultured with higher amplification efficiency and longer in vitro culture time. The present invention also provides methods and applications for using the culture medium to culture primary human acute lymphoblastic leukemia cells in vitro for drug efficacy evaluation and screening.

The present invention is in the field of in vitro assays, particularly in the field of pyrogen and endotoxin detection. The invention provides improved compositions suitable for use in animal-free testing such as for use in a monocyte activation test. The improved compositions allow for test responses with increased sensitivity, improved dynamic range, and improved goodness of fit.

The invention relates to a human brain glioma related fibroblast as well as an acquisition method and application thereof. The human brain glioma related fibroblast strain is named as G-CAF-1110, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.46060. The acquisition method of the human brain glioma related fibroblasts comprises a step of acquiring cells from brain glioma tissue fragments by adopting collagenase P digestive juice, a step of primary culture and a step of subculture, and a culture medium is a DMEM / F-12 culture solution and contains 5-12 vol% of human platelet lysate, 1.5-2.5 vol% of fetal calf serum and 0.8-1.2 vol% of mycillin. The cell can be used for screening medicines for treating human brain glioma and the like.

The invention discloses a human endothelial progenitor cell culture medium and application thereof in preparation of extracellular vesicles. The formula of the human endothelial progenitor cell culture medium is as follows: human platelet lysate with the volume concentration of 3-10%, VEGF (vascular endothelial growth factor) with the volume concentration of 60-200ng / mL, IGF (insulin-like growth factor) with the volume concentration of 20-100ng / mL, L-glutamine with the volume concentration of 2-10mM, sodium pyruvate with the volume concentration of 0.02-0.75 mM, glucocorticoid with the volume concentration of 50-250ng / mL and a reducing agent with the volume concentration of 50-200mu M are added into a basic cell culture medium; the human endothelial progenitor cells are human placenta tissue-derived endothelial progenitor cells. Animal-derived reagents are not involved, the price is low, the number of EPCs extracellular vesicles obtained through amplification is large, the purity is high, and the skin wound repairing effect is good. The extracellular vesicles are easy to produce on a large scale, convenient to store and control batch quality, simple to obtain and use and free of immunological rejection.

This invention belongs to the field of biotechnology and relates to a method for tracking and assessing the metabolic distribution of platelets in organs based on mitochondrial DNA. Specifically, this invention constructs a humanized mouse model, injects exogenous platelets into the humanized mouse model, and sequences the specific SNVs of the exogenous platelet mitochondrial DNA to trace the metabolic distribution of human platelets or human drug-loaded platelets. The safety is assessed by analyzing the metabolic distribution when human platelets are used as a delivery system.

The invention belongs to the technical field of cell culture, and provides a mesenchymal stem cell 3D culture medium, which comprises a basic culture medium and an additive, the additive is composed of lipid, a metabolism regulator, adherin, a buffering agent and human platelet lysate. According to the mesenchymal stem cell 3D culture medium provided by the invention, through the synergistic effect of all the components, the attachment rate of cells on a microcarrier can be remarkably increased, formation and growth of cell three-dimensional aggregates are promoted, cell senescence can be remarkably reduced, and the proliferation efficiency is improved. In addition, the mesenchymal stem cells obtained through culture of the 3D culture medium can improve the treatment effect on ARDS. The culture medium is simple in component and good in culture effect, and can be widely applied to 3D culture of mesenchymal stem cells of various sources.

The invention discloses a method for efficiently constructing a cell sphere barrier with a specific structure by using a sequential culture medium strategy. The method comprises the following steps: firstly, respectively carrying out cell multiplication culture by adopting respective applicable culture media of mesenchymal stem cells or endothelial cells, and then synchronously or stepwise inoculating the cells by adopting a specific culture medium to carry out three-dimensional cell culture. Then, in a DMEM / F12 culture medium containing human platelet lysates, the human platelet lysates are stably polymerized into cell spheres with specific structures. Due to the specific space structure of the sphere, the sphere has good application potential in the aspects of in-vitro cell migration and invasion research, organoid development, cell barrier mechanism research and the like.

The invention discloses a phototherapy nano system for removing candida and lactobacillus, a preparation method of the phototherapy nano system and application of the phototherapy nano system in preparation of drugs for treating vulvovaginal candidiasis. The phototherapy nano system comprises cell membranes with GPIb, GPIIb / IIIa and gC1q-R / P32 receptors; polylactic acid-glycolic acid copolymer (PLGA) nanoparticles wrapped by a cell membrane; a photosensitizer is embedded on the surface of the cell membrane; the preparation method comprises the following steps: extracting cell membrane PM of human platelets; the method comprises the following steps: premixing an IR780 photosensitizer and a cell membrane PM, and embedding IR780 into the cell membrane PM through ultrasonic under a water bath condition to obtain PM (IR); the preparation method comprises the following steps: carrying out water bath ultrasonic treatment on PM (IR) and polylactic acid-glycolic acid copolymer PLGA nanoparticles, and coating the PM (IR) on the polylactic acid-glycolic acid copolymer PLGA nanoparticles to obtain the PM (IR)-NP bionic nanoparticles. The problems of high recurrence rate, drug tolerance and vaginal flora ecological imbalance in the treatment of the recurrent vulvovaginal candidiasis can be relieved.

The invention discloses colloidal gold chromatography test paper and a kit for detecting platelet CD36 antigen, the colloidal gold chromatography test paper comprises a bottom plate, a sample pad, a gold-labeled combination pad, a nitrocellulose membrane and a water absorption pad, the gold-labeled combination pad is coated with a colloidal gold labeled mouse anti-human CD36 IgG2a monoclonal antibody and a colloidal gold labeled quality control rabbit IgG polyclonal antibody; the nitrocellulose membrane is provided with a detection line coated with a human platelet CD36 antigen capture antibody and a quality control line coated with quality control goat anti-rabbit polyclonal antibody molecules. When the kit is used for detecting the CD36 antigen, a detected sample is fully split by the platelet lysis buffer and then is added into the sample adding hole of the kit, and a detection result can be observed after waiting for 10-15 minutes. By adopting the detection mode provided by the invention, the CD36 antigen on the human platelets can be quickly, simply, conveniently, sensitively and specifically detected.

The invention provides a liquid composition containing recombinant human platelet-derived growth factors. The composition comprises the following components: polyvinyl alcohol, hydroxypropyl methyl cellulose, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, mannitol and the like. The invention also provides a preparation method of the composition and application of the composition in preparation of corneal injury treatment medicines. The eye drops prepared from the composition disclosed by the invention have good stability and safety, and have a good effect in repairing corneal injury.

This invention provides a culture medium for closed-system culture of mesenchymal stem cells, comprising the following components: 1% (v / v) human platelet lysate, 10-15 g / L basal culture medium powder, 15-20 mM HEPES, 1.0-2.0 g / L sodium bicarbonate, and 0.1-1.0 g / L sodium chloride; wherein the basal culture medium powder includes non-essential amino acids, D-glucose, L-glutamine, specific growth factors, inorganic salts, and vitamins. Using the culture medium provided by this invention for mesenchymal stem cell culture eliminates the need for exogenous CO2, reducing equipment costs and process complexity; furthermore, it results in cell viability ≥97%, more concentrated particle size distribution, and more stable expression of surface markers, which is beneficial for large-scale production.

This invention discloses a gel formulation containing human platelet-derived growth factor (PDGF). The components and dosages are as follows: PDGF 50,000-300,000 IU / mL, sodium carboxymethyl cellulose 3.0-4.5%, polyvinyl alcohol 0.5-3%, disodium hydrogen phosphate dodecahydrate 0.258-0.774%, sodium dihydrogen phosphate monohydrate 0.039-0.116%, sodium chloride 0.6-0.95%, methylparaben 0.15-0.18%, propylparaben 0.015-0.020%, and protein protectant 0.4-0.6%. This invention, through optimization of the gel matrix combination and ratio, enables the gel to possess excellent stability and skin adhesion, improves the biological activity of the formulation, and promotes cell proliferation and wound repair at the wound site. It also offers advantages such as a pleasant user experience and simple processing.

Methods provided for producing human platelet lysates (HPL) typically from expired platelet units that were initially manufactured to be infused into patients. Whole blood units from which platelets will be prepared for transfusion are maintained at a temperature cooling toward room temperature. The platelet lysate produced by the method can be formed from platelets that have been removed from the refrigerated whole blood unit more than 8 hours after phlebotomy.